Myriad Loses Bid To Block Ambry Cancer Tests In Patent Row
A Utah federal judge on Monday halted Myriad Genetics Inc.'s quest to block sales of Ambry Genetics Corp. cancer-testing products it claims infringe several of its patents, including five tackled in...To view the full article, register now.
Already a subscriber? Click here to view full article